Phase I study of oral ridaforolimus in combination with paclitaxel and carboplatin in patients with solid tumor cancers-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Phase I study of oral ridaforolimus in combination with paclitaxel and carboplatin in patients with solid tumor cancers

Published:2017-06-08 Issue:1 Volume:17 Page:
ISSN:1471-2407
Container-title:BMC Cancer
language:en
Short-container-title:BMC Cancer

Author:

Chon Hye Sook,Kang Sokbom,Lee Jae K.,Apte Sachin M.,Shahzad Mian M.,Williams-Elson Irene,Wenham Robert M.

Funder

National Cancer Institute

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Genetics,Oncology

Link

http://link.springer.com/content/pdf/10.1186/s12885-017-3394-2.pdf

Reference29 articles.

1. Schmelzle T, Hall MN. TOR, a central controller of cell growth. Cell. 2000;103(2):253–62.

2. Dancey JE, Monzon J. Ridaforolimus: a promising drug in the treatment of soft-tissue sarcoma and other malignancies. Future Oncol. 2011;7(7):827–39.

3. Shaw RJ, Cantley LC. Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature. 2006;441(7092):424–30.

4. Fasolo A, Sessa C. mTOR inhibitors in the treatment of cancer. Expert Opin Investig Drugs. 2008;17(11):1717–34.

5. Rivera VM, Squillace RM, Miller D, Berk L, Wardwell SD, Ning Y, et al. Ridaforolimus (AP23573; MK-8669), a potent mTOR inhibitor, has broad antitumor activity and can be optimally administered using intermittent dosing regimens. Mol Cancer Ther. 2011;10(6):1059–71.

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical research progress of ridaforolimus (AP23573, MK8668) over the past decade: a systemic review;Frontiers in Pharmacology;2024-03-22

2. Novel Therapies and Emerging Actives for Treatment of Luminal Breast Cancer;Research Journal of Pharmacy and Technology;2023-11-30

3. Drug repositioning via host-pathogen protein-protein interactions for the treatment of cervical cancer;Frontiers in Oncology;2023-01-25

4. Advanced and recurrent endometrial cancer: State of the art and future perspectives;Critical Reviews in Oncology/Hematology;2022-12

5. The Role of AKT in Soft Tissue Sarcoma: Review and Insights;Molecular Cancer Research;2022-07-07

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3